EPISODE · Dec 6, 2019 · 21 MIN
Robert Bilkovski, CEO at medAppraise Inc.
from Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere · host Julio G. Martinez-Clark
Robert serves as the CEO for medAppraise Inc., a health technology startup focused on transforming the health and wellness of employees in large industrial corporations through the use of a state-of-the-art musculoskeletal health evaluation solution. In addition, Robert currently serves as president of RNB Ventures Consulting Inc, which is a medical device/technology consultancy firm. RNB Ventures Consulting aim is to provide medical/clinical affairs consulting expertise to medical device and IVD manufacturers on medical risk determinations and pre-submission expertise for new IVD assays. Prior to that, Robert served in medical leadership roles at Becton Dickinson in the Corporate Clinical Development organization; at Abbott Laboratories Molecular Diagnostics division, GE Healthcare – Lifecare Solutions and Hospira. Robert graduated with a Doctor of Medicine from Rosalind Franklin University/The Chicago Medical School, completed residency training in emergency medicine at Henry Ford Hospital in Detroit, MI (served as Chief Resident) and graduated with a Masters in Business Administration from the University of Notre Dame. Robert holds an active license to practice medicine in the United States.
What this episode covers
Robert serves as the CEO for medAppraise Inc., a health technology startup focused on transforming the health and wellness of employees in large industrial corporations through the use of a state-of-the-art musculoskeletal health evaluation solution. In addition, Robert currently serves as president of RNB Ventures Consulting Inc, which is a medical device/technology consultancy firm. RNB Ventures Consulting aim is to provide medical/clinical affairs consulting expertise to medical device and...
NOW PLAYING
Robert Bilkovski, CEO at medAppraise Inc.
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m